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Abstract
TNF-alpha plays an important role in trypanocidal mechanisms and is related to tissue injury. This cytokine has been
detected in the heart of human chagasic patients where it is associated with tissue damage. This study investigated whether
TNF-alpha levels and the presence of genetic polymorphisms are associated with the presence of T. cruzi infection and/or
with the development of the cardiac form in chronic chagasic patients. Genomic DNA of 300 subjects from an endemic area
was extracted and analyzed by PCR using specific primers. TNF-alpha was assayed in culture supernatants by ELISA. An
association was observed between the absence of the TNF-238A allele and negative serology. Furthermore, seropositive
individuals carrying the TNF-238A allele produced significantly higher TNF-alpha levels without stimulation (p=0.04) and
after stimulation with LPS (p=0.007) and T. cruzi antigens (p=0.004). The present results suggest that the polymorphism at
position -238 influences susceptibility to infection and that this allele is associated with higher TNF-alpha production in
seropositive individuals.
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Introduction
Chagas disease is an important chronic infection caused by the
protozoan Trypanosoma cruzi. The disease continues to be a major
public health problem in most Latin America countries, affecting
around 9 million people [1]. In addition, Chagas disease is an
emerging health problem in non-endemic areas because of the
increasing migration of individuals [2]. Chagas disease has two
successive phases. The acute phase is usually asymptomatic or
characterized by the presence of fever, discomfort, tachycardia
and high parasitemia [3,4]. Manifestations of the acute disease
resolve spontaneously in about 90% of infected individuals even if
the infection is not treated with trypanocidal drugs. About 60–
70% of these patients will never develop clinically apparent
disease. These patients have the indeterminate form of chronic
Chagas disease, which is characterized by positivity for antibodies
against T. cruzi in serum, a normal 12-lead electrocardiogram
(ECG), and normal chest, esophagus and colon exams. The
remaining 30–40% of patients will subsequently develop a
determinate form of chronic disease: cardiac, digestive (mega-
esophagus and megacolon), or cardiodigestive [2].
Geographic variations exist in the severity and prevalence of the
clinical forms of Chagas disease, but the reasons for this clinical
and epidemiological heterogeneity are unknown [5]. Possible
causes include variations in the genetic constitution of the host,
especially genes related to the immune system since the latter is
involved in the control of parasitism and in tissue injury. In
Chagas disease, like in other parasitic diseases, the causal factor
(i.e., the infectious agent) is necessary but often insufficient for
clinical manifestation of the disease [6]. The complexity of the
host-parasite relationship in Chagas disease suggests the involve-
ment of different components of the immune system.
The genes for tumor necrosis factor-alpha (TNF-alpha) and
lymphotoxin-alpha, which are located in the MHC III region on
chromosome 6, are closely linked to the HLA class I and class II
genes [7]. TNF-alpha, which is mainly produced by monocytes
and activated T cells, plays an important immunoregulatory role
[8]. This cytokine contributes to the pathogenesis of Chagas
disease due to its role in both trypanocidal mechanisms and tissue
injury. Production of this cytokine at high levels has been
demonstrated in experimental models during the acute phase [9]
and its function as an inducer of iNOS is important for the control
of parasite growth [10,11]. TNF-alpha has been detected in the
heart tissue of experimentally infected animals [12], as well as in
inflammatory exudate cells of human chagasic myocarditis [13].
These findings suggest that individual differences in TNF-alpha
production may be responsible for the variation among individ-
uals. These differences are the result of polymorphisms present in
the general population. Polymorphisms in the promoter region of
the TNF-alpha gene have been known for a long time and might
be involved in the control of the expression of this gene [14,15].
The presence of these polymorphisms has been associated with
susceptibility to certain inflammatory and infectious diseases [16–
18].
Recent studies have investigated the role of TNF-alpha gene
polymorphisms in Chagas disease [19–22], but none of those
www.plosntds.org 1 March 2011 | Volume 5 | Issue 3 | e976studies evaluated a population from an endemic area or used the
clinical assessment criteria established here. The present study
investigated TNF-alpha production by peripheral blood cells and
whether the presence of G substitutions at positions -238 and -308
are associated with the presence of T. cruzi infection and/or the




The study was performed in the municipality of A ´gua Comprida
(20u39230S, 48u69310W at 540 m above sea level), situated in the
Vale do Rio Grande, southern region of Tria ˆngulo Mineiro, Minas
Gerais State, Brazil. The town was endemic for Chagas disease and
was included in the first National Campaign against T. cruzi that
started in 1975. Epidemiological and entomological data demon-
strated the interruption of vector transmission of the parasite to
humansin 1999, and an international commission certifiedBrazil to
be free of transmission in 2005 [23,24].
Study population
A total of 300 unrelated individuals agreed to participate in the
study. Only subjects who were 25 years or older were included
(mean age: 51.2614.4; range: 25–91 years), since they corre-
sponded to the youngest seropositive individuals of the sample
studied. Serological screening for anti-T. cruzi antibodies showed
that 25.6% of these subjects were positive and 74.5% were
negative [25]. All HIV-seropositive individuals were excluded
from the study. The treatment criteria did not exclude any patient.
Ethics statement
The study was approved by the Research Ethics Committee of
Universidade Federal do Tria ˆngulo Mineiro, Brazil (protocol 343).
All individuals provided written informed consent.
Serological test
The presence or absence of T. cruzi infection was evaluated by
passive hemagglutination (Salck Laboratory, Sa ˜o Paulo, Brazil),
enzyme-linked immunosorbent assay (Abbott, Brazil) and indirect
immunofluorescence using fluorescein isothiocyanate (FITC)-
conjugated to rabbit anti-human IgG (Sigma). The assays were
performed according to manufacturer instructions and the results
are expressed quantitatively. A subject who presented at least two
positive tests was defined as positive [25].
Characterization of clinical forms
Patients infected with T. cruzi were submitted to clinical
examination, electrocardiography and chest, esophagus and colon
contrast X-ray exams for classification into the cardiac, digestive,
mixed, or indeterminate form [26,27]. Patients with the cardiac
form were classified according to the Criteria Committee of the
New York Heart Association [28]. Appropriate statistical analysis
was not possible because of the small sample size.
Blood collection and cell culture
Peripheral blood samples (20 mL) were collected with a
vacuum system using heparin as anticoagulant. Peripheral blood
mononuclear cells (PBMC) were separated by density centrifu-
gation on a Ficoll-Hypaque gradient (Pharmacia) according to
manufacturer recommendations. After separation, the cells were
washed by centrifugation in RPMI medium (Gibco) and
resuspended in RPMI medium supplemented with 5% fetal
bovine serum (Gibco), 2 mM L-glutamine (Gibco), 50 mM 2-
mercaptoethanol (Merck), and 40 mg/mL gentamicin. PBMC
(2610
6 cells/well) were cultured in the presence of 5 mg/mL T.
cruzi (strain Y) antigens, 2 mg/mL Salmonella typhimurium lipopoly-
saccharide (LPS) (Sigma), and 5 mg/mL phytohemagglutinin
(PHA) (Sigma). The plates were incubated at 37uCi na5 %C O 2
atmosphere for 48 h. The culture supernatants were collected
a n ds t o r e da t270uC.
Quantification of TNF-alpha by ELISA
For TNF-alpha titration, microplates (Nunc) were sensitized
overnight with anti-TNF-alpha mAb (Pharmingen). Nonspecific
binding was prevented by incubating the plates with 2% BSA
(Sigma) in PBS. The plates were incubated overnight with 100 mL
of the culture supernatants in PBS diluted 1:2, 2% BSA, and
recombinant human TNF-alpha (Pharmingen). The plates were
then washed four times with PBS and 0.05% Tween 20 and
incubated with biotinylated anti-TNF-alpha mAb (Pharmingen)
for 2 h, followed by washing and incubation for 2 h with
streptavidin-conjugated alkaline phosphatase. Finally, the plates
were washed four times and enzymatic activity was developed by
incubating the plates with p-nitrophenyl phosphate (Sigma).
Absorbance was read at 405 nm in a microplate reader (BioRad).
The sensitivity limit of the test was 10 pg/mL.
Genomic DNA purification
The mass of red and white blood cells was submitted to osmotic
lysis using Tris-EDTA lysis buffer (20:5) consisting of 1 M Tris-
HCl and 0.5 M EDTA, pH 8. The samples were centrifuged at
least three times at 13346g for 15 min at controlled room
temperature (approximately 27uC).
For DNA extraction, the samples were treated by two different
techniques depending on the amount of red blood cells remaining
in the leukocyte pellet to guarantee the best quality DNA. A
commercially available kit (DNAzol, Gibco) was used for samples
containing few red blood cells and phenol-chloroform extraction
was used for samples containing higher amounts of red blood cells.
The samples were resuspended in water and DNA was analyzed
by 1% agarose gel electrophoresis.
Author Summary
Chagas disease is an important parasitic disease that has no
cure. The pathogenesis of the disease is still not completely
understood.Studiesusingcandidategenesareimportantto
better understand the differences between individuals that
lead to such heterogenous disease. TNF-alpha is a cytokine
involved in the control of parasitemia during the acute
phase and in cardiac injury during the chronic phase. The
TNF-alpha gene is located in an important region of the
MHC and its polymorphisms are associated with many
parasitic and infectious diseases such as cerebral malaria
and leishmaniasis. These studies are important since they
were conducted in the same regions and involved
populations leaving in the same conditions. The present
study shows that patients with the indeterminate form
produce higher levels of TNF-alpha than cardiac patients.
The data suggest a control mechanism between inflamma-
tory and regulatory cytokines. In addition, the presence of
the TNF-238G allele contributes to the development of
negative serology. We show that CD8
+ T lymphocytes and
macrophages are the main cells producing TNF-alpha. This
study is an important contribution to explain the patho-
genesis of Chagas disease.
TNF-alpha in Chagas Disease
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Polymorphisms in the promoter region of the TNF-alpha gene
were determined by PCR amplification, followed by digestion with
appropriate restriction enzymes. For TNF-238G/A [15], PCR
was carried out in a volume of 30 mL containing 11.70 mL sterile
and filtered Milli-Q water, 3.0 mL1 0 6 buffer without MgCl2
(Gibco), 1.0 mL 50 mM MgCl2 (Gibco), 3.0 mL 2 mM dNTPs
(Invitrogen), 3.0 mL of each primer (40 nmol 238F: 59 GGT CCT
ACA CAC AAA TCA GT 39, and 43.2 nmol 238R: 59 CAC TCC
CCA TCC TCC TCC CTG GTC 39) (Gibco), 0.30 mL (500 units,
5U / mL) Taq DNA polymerase (Gibco), and 5.0 mL genomic
DNA at a concentration of 20 mg/mL. The following PCR
conditions were used: 5 min at 95uC for initial denaturation and
35 cycles at 95uC for 1 min (denaturation), 55uC for 45 s (primer
annealing), and 72uC for 45 s (extension), followed by a final
extension step at 72uC for 3 min. Next, RFLP was performed
using 0.1 mL AvaII (10,000 U/mL) (New England Biolabs), 1.0 mL
NE 4 buffer provided with the restriction enzyme, 0.4 mL sterile
and filtered Milli-Q water, and 8.5 mL of the PCR product in a
final volume of 10 mL. The samples were incubated for
approximately 18 h at controlled room temperature (approxi-
mately 27uC). The digestion products were analyzed on 12%
polyacrylamide gel (37:5:1) stained with 1% silver nitrate.
Digestion of the PCR products from patients homozygous for
the TNF-238A allele (-238A/A) generated only one 71-base pairs
(bp) fragment, whereas those from patients homozygous for the
TNF-238G allele (-238G/G) were completely digested (51 and
20 bp). All three fragments (71, 51 and 20 bp) were present in
heterozygous patients.
For TNF-308G/A [14], the PCR mixture contained 11.70 mL
sterile and filtered Milli-Q water, 3.0 mL1 0 6 buffer without
MgCl2 (Gibco), 1.0 mL 50 mM MgCl2 (Gibco), 3.0 mL2 m M
dNTPs (Invitrogen), and 3.0 mL of each primer (38 nmol -308F: 59
AGG CAA TAG GTT TTG AGG GCC AT 39, and 45 nmol
-308R: TCC TCC CTG CTC CGA TTC CG 39) (Gibco),
0.30 mL (500 units, 5 U/mL) Taq DNA polymerase (Gibco), and
5.0 mL genomic DNA at a concentration of 20 mg/mL in a final
volume of 30 mL. The following PCR conditions were used: 5 min
at 95uC for initial denaturation, followed by 35 cycles at 95uC for
1 min (denaturation), 52uC for 45 s (primer annealing), and 72uC
for 45 s (extension), followed by a final extension step at 72uC for
3 min. For RFLP, the mixture contained 0.1 mL NcoI (10 U/mL)
(Gibco), 1.5 mL REACT 3 buffer provided with the restriction
enzyme, 10.5 mL sterile and filtered Milli-Q water, and 3.0 mLo f
the PCR product in a final volume of 12.1 mL. The samples were
incubated for approximately 18 h at 37uC. The digestion products
were analyzed on 10% polyacrylamide gel (37:5:1) stained with
1% silver nitrate. Digestion of the PCR products from patients
homozygous for the TNF-308A allele generated only one 107-bp
fragment, whereas those from patients homozygous for the TNF-
308G allele were completely digested (87 and 20 bp). All three
fragments (107, 87 and 20 bp) were present in heterozygous
patients.
Flow cytometry immunostaining and data acquisition
The following antibodies purchased from BD Pharmingen were
used: FITC anti-CD8, FITC anti-CD14, and PE-Cy5 anti-CD4.
PE anti-TNF-alpha and appropriate isotype controls were used.
All of these antibodies were used according to manufacturer
instructions. PBMC were recovered from 48 h cell cultures in the
presence of T. cruzi antigens or medium alone. The cells were
transferred (2610
5 cells/tube) to 5 mL polystyrene tubes (FalconH)
and washed once with cold buffer (PBS-5% BSA) by centrifugation
at 4006g for 10 min at 20uC. Cell pellets were resuspended in
100 mL PBS-BSA buffer and reacted with FITC anti-CD8 plus
PE-Cy5 anti-CD4 mAb or FITC anti-CD14 for surface labeling.
After 30 min of incubation in the dark at 4uC, the samples were
washed three times in buffer by centrifugation at 3006g for 5 min
at 20uC and fixed and permeabilized with freshly prepared
Fixation/Permeabilization Working Solution (Pharmingen) for
30 min at 4uC, followed by two washed in 2 mL buffer. After the
last wash, the cell pellets were resuspended in 100 mL1 X
Permeabilization Buffer and reacted with PE anti-TNF-alpha at
4uC in the dark. After 30 min of incubation, the cells were washed
twice with 2 mL 1X Permeabilization Buffer and then resus-
pended in 1% paraformaldehyde in Dulbecco’s PBS (Sigma) for
analysis. A total of 20,000 events/tube were acquired using a
FACScaliburH flow cytometer (Becton Dickson). The Cell
Quest
TM software provided by the manufacturer was used for
data acquisition and analysis.
Statistical analysis
Genotype and allele frequencies were analyzed statistically by
the chi-square test. The strength of association was estimated using
odds ratios and 95% confidence intervals (CI). The Mann-
Whitney or Kruskal-Wallis test was used to analyze the association
of TNF-alpha levels with genotypes, allele frequency, serology, and
clinical forms. The unpaired t-test was used to analyze the
association of intracellular TNF-alpha expression with the cardiac
or indeterminate form. Analysis was performed using the StatView
software, version 4.57 (Abacus Concepts, USA). The level of
significance was set at 5% (p,0.05).
Results
Characteristics of the sample
A total of 300 individuals were included in the study, 168 (56%)
with positive serology for T. cruzi and 132 (44%) with negative
serology. All subjects were from the same endemic area. A total of
214 subjects were genotyped to position -238. Of these, 100
individuals were seropositive for T. cruzi and 114 were seroneg-
ative. All 300 individuals were genotyped to position -308. Of
these, 168 individuals were seropositive for T. cruzi and 132 were
seronegative.
Clinical classification was possible in 119 of the 168 subjects
infected with T. cruzi. Sixty-six (55.46%) had the cardiac form and
53 (44.54%) had the indeterminate form. Only 39 and 66 patients
with the cardiac form were genotyped to positions -238 and -308,
respectively. Among the indeterminate patients, 36 were geno-
typed to position -238 and 53 to position -308. Clinical
manifestations were only compared between patients with the
cardiac and indeterminate forms.
TNF-alpha production
Seronegative individuals produced higher levels of TNF-alpha
than seropositive subjects without stimulation (Mann-Whitney,
p=0.0003) and seropositive individuals produced more TNF-
alpha than seronegative individuals after PHA stimulation (Mann-
Whitney, p=0.01) (Figure 1A). TNF-alpha levels were signifi-
cantly higher in patients with the indeterminate form than in
cardiac patients without stimulation (Mann-Whitney, p=0.01),
after LPS stimulation (Mann-Whitney, p=0.005), and after
stimulation with T. cruzi antigen (Mann-Whitney, p=0.01)
(Figure 1B). Comparison of seronegative individuals with cardiac
and indeterminate patients showed that cardiac patients produced
higher levels of TNF-alpha than seronegative individuals without
stimulation (Mann-Whitney, p=0.0002) and after LPS stimulation
(Mann-Whitney, p=0.005) (Figure 1B). Moreover, indetermi-
TNF-alpha in Chagas Disease
www.plosntds.org 3 March 2011 | Volume 5 | Issue 3 | e976Figure 1. Levels of TNF-alpha in culture supernatants. TNF-alpha was assayed by ELISA in supernatants of PBMC cultured for 48 h in the
absence of any stimulus and in the presence of T. cruzi antigen, LPS and PHA. A. Subjects were grouped according to positive or negative serology;
*p=0.0003 (Mann-Whitney test). B. Subjects were grouped according to the cardiac or indeterminate form and negative serology: Cardiac x negative
to medium: p=0.0002; cardiac x negative to LPS stimulation: p=0.005; indeterminate x negative to PHA: p=0.03; cardiac x indeterminate to medium:
p=0.01; to LPS: p=0.005; to T. cruzi antigens: p=0.01 (Mann-Whitney test). Results are expressed as pg/mL. The horizontal line indicates the median,
bars the 25% and 75% percentiles, and vertical lines the 10% and 90% percentiles.
doi:10.1371/journal.pntd.0000976.g001
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seronegative individuals after PHA stimulation (Mann-Whitney,
p=0.03) (Figure 1B).
Association of TNF-alpha polymorphisms with disease
Analysis was performed between genotypes and infection
determined by serology. Table 1 shows the distribution of the
TNF-238G/A and TNF-308G/A genotypes. No association was
observed between genotypes and serology (X
2, TNF-238G/A
p=0.08; TNF-308G/A p=0.41). When the TNF-238AA and
TNF-238GA genotypes were grouped as allele A presence and the
genotype TNF-238GG was considered to be allele A absence, the
data verified that allele A absence was more frequent among
seronegative individuals (X
2, p=0.03) (Table 2). An odds ratio of
1.846 was observed (CI=1.057 to 3.223).
Table 3 shows the distribution of the TNF-238G/A and TNF-
308G/A genotypes only among individuals with positive serology
divided into the cardiac and indeterminate clinical forms. No
significant associations were observed (X
2, TNF-238G/A p=0.28;
TNF-308G/A p=0.64).
TNF-alpha production and genotypes
There were no differences in TNF-alpha levels produced by
seropositive and seronegative individuals carrying different
genotypes of the TNF-alpha polymorphisms position -238
(Figure 2) and position -308 (data not shown). On the other
hand, higher levels of TNF-alpha were observed in individuals
carrying the TNF-238A allele after LPS stimulation (Mann-
Whitney, p=0.045) when all subjects were analyzed together
(Figure 3A). No differences were observed when the individuals
were grouped according to negative serology (data not shown).
Interestingly, when seropositive individuals were analyzed alone,
higher TNF-alpha levels were observed in those carrying the TNF-
238A allele without stimulation (Mann-Whitney, p=0.04), after
stimulation with T. cruzi antigen (Mann-Whitney, p=0.004), and
LPS stimulation (Mann-Whitney, p=0.007) (Figure 3B).
Characterization of TNF-alpha-producing cells
The presence of intracellular TNF-alpha was analyzed by flow
cytometry in 48-h cultured cells. In the absence of stimulation,
1.18% and 1.83% of CD8
+ cells were positive for TNF-alpha in
patients with the cardiac and indeterminate forms, respectively. In
CD4
+ cells, the rate of TNF-alpha production was 2.60% in
cardiac patients and 1.713% in indeterminate patients. No
association was observed between the cell type and clinical form
presented by the patient (data not shown). After stimulation with
T. cruzi antigens, 28.47% and 38.80% of CD8
+ cells were positive
for TNF-alpha in patients with the cardiac and indeterminate
forms, respectively. In CD4
+ cells, positivity for TNF-alpha was
2.78% for cardiac patients and 6.54% for indeterminate patients
(Figure 4). This difference was statistically significant (unpaired t-
test; p=0.044). Two levels of TNF-alpha production were
observed in CD14
+ cells, low and high levels. In cardiac patients,
63.36% and 3.76% of CD14
+ cells were classified as low and high
producers, respectively. These percentages were 29.96% and
0.70% in patients with the indeterminate form (Figure 4).
Discussion
The immune response plays an important role in the control of
T. cruzi infection. TNF-alpha is an important cytokine involved in
parasite control during the acute phase [9–11]. However, there are
few studies in the literature discussing its role during the chronic
phase. Some studies have suggested the involvement of TNF-alpha
in the development of the cardiac form [13,29,30], but its role in
the control of parasite growth in humans and the consequent
Table 1. TNF-alpha genotypes found in subjects from an endemic area according to the presence or absence of infection.
Seropositive individuals Seronegative individuals p value (X
2)
Genotype N % N %
TNF-238AA 26 26 22 19.30
TNF-238GA 20 20 14 12.3 p=0.08
TNF-238GG 54 54 78 68.4
Total 100 100 114 100.0
TNF-308AA 06 3.6 08 6.1
TNF-308GA 52 31.0 34 25.8 p=0.41
TNF-308GG 110 65.4 90 68.1
Total 168 100.0 132 100.0
doi:10.1371/journal.pntd.0000976.t001
Table 2. Presence and absence of the TNF-238A allele in seropositive and seronegative individuals.
Seropositive individuals Seronegative individuals p value (X
2)
N%N%
Absence of TNF-238A allele 54 54.0 78 68.4 p=0.03
Presence of TNF-238A allele 46 46.0 36 31.6
Total 100 100.0 114 100.0
doi:10.1371/journal.pntd.0000976.t002
TNF-alpha in Chagas Disease
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present study conducted on individuals (control group and infected
individuals) from an endemic area in the central region of Brazil
(A ´gua Comprida) provided important results. This area was
included in the first national campaign against Chagas disease that
started in 1950 [31]. These characteristics result in homogeneous
population exposition and similar environmental and social
conditions, thus reducing possible confounding factors.
Higher TNF-alpha levels were produced by seronegative
individuals without stimulation, indicating that individuals who
did not acquire the infection are able to produce TNF-alpha
spontaneously. High basal levels of TNF-alpha may improve the
host defense against T. cruzi, possibly by modulating the expression
of iNOS and adhesion molecules involved in rolling, adhesion and
extravasation during inflammatory events in response to T. cruzi
invasion [10–12]. Higher levels of TNF-alpha were observed in
seropositive individuals compared to seronegative subjects. This
finding might be due to polyclonal expansion in response to
nonspecific stimulation.
Analyzing the development of the clinical form, TNF-alpha
levels were significantly higher in patients with the indeterminate
form than in those with the cardiac form. Comparison of cardiac
patients with the control group showed higher levels of TNF-a in
the cardiac group without stimulation and after LPS stimulation.
Furthermore, indeterminate patients produced higher level of the
cytokine after PHA stimulation. This fact suggests that TNF-alpha
production by PBMC might be more important for the ability of
the cytokine to control parasite growth than for promoting tissue
damage or the development of heart lesions. It is important to
point out that in the present study most patients classified as
having the cardiac form did not exhibit severe heart involvement
such as heart failure. Severe and end-stage Chagas disease has
been associated with high levels of TNF-alpha [29,30,32]. Our
results differ from those reported by Ferreira et al. [29] and
Talvani et al. [30]. However, a previous study from our group
analyzing plasma TNF-alpha levels was unable to show differences
between the clinical forms of chronic Chagas disease [33]. TNF-
alpha plays a potential dual role, controlling parasite growth or
promoting tissue damage. Moreover, TNF-alpha is able to
stimulate IL-10 synthesis [34], a regulatory cytokine that
contributes to the control of inflammation. A recent experimental
study demonstrated that the blockage of TNF-alpha with
Etanercept enhances left ventricular dysfunction in T. cruzi-
induced chronic cardiomyopathy [35]. In this respect, the delicate
balance between the ability of TNF-alpha to control parasite
growth and to promote tissue damage may be responsible for
human resistance/susceptibility to Chagas disease. Not only the
level of this cytokine, but the cells involved in its production and
the elapsed time after interaction with the parasite should be
investigated to improve the current understanding of the role of
TNF-alpha in Chagas disease.
Table 3. TNF-alpha genotypes found in subjects from an
endemic area according to clinical form.
Cardiac form Indeterminate form p value (X
2)
Genotype N % N %
TNF-238AA 10 25.6 8 22.2
TNF-238GA 6 15.4 11 30.5 p=0.28
TNF-238GG 23 59.0 17 47.3
TOTAL 39 100.0 36 100.0
TNF-308AA 4 6.1 2 3.8
TNF-308GA 21 31.8 14 26.4 p=0.64
TNF-308GG 41 62.1 37 69.8
TOTAL 66 100.0 53 100.0
doi:10.1371/journal.pntd.0000976.t003
Figure 2. Levels of TNF-alpha in culture supernatants. TNF-alpha was assayed by ELISA in supernatants of PBMC cultured for 48 h in the
absence of any stimulus and in the presence of T. cruzi antigen, LPS and PHA. Subjects were grouped according to TNF-238A genotypes (TNF-238AA,
TNF-238GA and TNF-238GG). Individuals with positive and negative serology were analyzed. Results are expressed as pg/mL. The horizontal line
indicates the median, bars the 25% and 75% percentiles, and vertical lines the 10% and 90% percentiles.
doi:10.1371/journal.pntd.0000976.g002
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evidence of an association between the absence of allele A at
position -238 and seronegativity. We observed that individuals
carrying the TNF-238A allele produce higher levels of TNF-a
than those without the allele. This result suggests that the TNF-
alpha polymorphism affects gene expression and that this effect
depends on the cell population and on the strength of the stimulus
since no differences were observed after PHA stimulation.
Moreover, infected individuals carrying the TNF-238A allele
produced higher levels of TNF-alpha than those without allele A.
This result suggests that the -238 polymorphism exerts its potential
function in infected subjects, probably as a result of clonal
expansion and immunoregulatory mechanisms established during
infection. The effect of the polymorphism might be more
pronounced under these conditions. No significant association
was established for the -308 polymorphism.
Figure 3. Levels of TNF-alpha in culture supernatants. TNF-alpha was assayed by ELISA in supernatants of PBMC cultured for 48 h in the
absence of any stimulus and in the presence of T. cruzi antigen, LPS and PHA. A. Subjects with positive serology and negative serology were grouped
according to the presence or absence of the TNF-238A allele; *p=0.045 (Mann-Whitney test). B. Only subjects with positive serology were grouped
according to the presence or absence of the TNF-238A allele; * p=0.04 compared to medium, p=0.004 compared to T. cruzi antigen, and p=0.007
compared to LPS (Mann-Whitney test). Results are expressed as pg/mL. The horizontal line indicates the median, bars the 25% and 75% percentiles,
and vertical lines the 10% and 90% percentiles.
doi:10.1371/journal.pntd.0000976.g003
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when compared to controls was demonstrated for various other
infectious diseases such as infection with Chlamydia trachomatis,
although these findings were not statistically significant [36].
Another study reported a higher bacteriological index in patients
with leprosy carrying the TNF-238A allele [37]. Homozygous
carriers of the TNF-238A allele were more frequent among
patients with psoriasis compared to controls [17]. In chronic and
active hepatitis C, the TNF-238A allele was more frequent in the
group of patients than in controls [18].
Other studies on Chagas disease were conducted in Peru,
Mexico and Brazil. The first study analyzed 87 healthy controls
and 85 individuals seropositive for anti-T. cruzi antibodies from an
endemic area in Peru. No significant differences were observed
between patients and controls or between asymptomatic individ-
uals and patients with cardiomyopathy for either polymorphic
region [19]. The second study compared 54 individuals seropos-
itive for Chagas disease and 169 controls from the Mexican
population. A higher frequency of the TNF-308A allele was
observed in chagasic patients compared to the control group.
Furthermore, the TNF-308A allele was more frequent among
patients with cardiopathy compared to asymptomatic individuals
[20]. However, these differences in the results might be attributed
to ethnic variations among different populations and to differences
in the study design and patient selection criteria. The third study
analyzed 42 patients with severe ventricular dysfunction. Patients
Figure 4. TNF-alpha expression on CD8
+ and CD4
+ lymphocytes. A. Percentage of TNF-alpha-producing cells among the CD8
+ and CD4
+
population of patients with the cardiac (gray bars) and indeterminate form (white bars) after 48 h of culture in the presence of T. cruzi antigens. B.
Percentage of TNF-alpha-producing cells among the CD14
+ population of patients with the cardiac (gray bars) and indeterminate form (white bars)
after 48 h of culture in the presence of T. cruzi antigens. For analysis, a gate was established using FSC and surface marker flowed by analysis of
intracellular TNF-alpha expression.
doi:10.1371/journal.pntd.0000976.g004
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survival time than those carrying other alleles [21]. The same
group compared 166 chronic Chagas disease patients with
cardiomyopathy to 80 asymptomatic patients, but observed no
significant association with TNF polymorphisms [22]. However,
none of the studies conducted in Brazil investigated the -238 gene
polymorphism or included subjects from endemic areas.
The present study differs from previous investigations because
all individuals were from a region of high endemicity, with a
greater probability of a more homogenous condition of exposure
and accurate clinical analysis after some years of infection,
permitting a sufficient time interval for the development of the
clinical forms of the disease. This is advantageous in relation to the
study’s characteristics, though it represents a disadvantage due to
the possible death of patients with more severe forms of the
disease. Furthermore, in the present study, functional analysis
showed that PBMC from seropositive individuals carrying the
TNF-238A allele produced significantly higher levels of TNF-
alpha when stimulated with LPS and T. cruzi antigens and in the
absence of any stimulus.
Other investigators observed higher TNF-alpha production by
LPS-stimulated PBMC in individuals homozygous for the TNF-
308A allele [38]. Studies using gene construction strategies in
which the promoter region of TNF was ligated to the luciferase
gene have also shown an increased production of TNF-alpha levels
among individuals with the TNF-308A allele [39,40]. A repressor-
binding site was identified at position -238 [41]. Thus, it is possible
that in certain cell types, the presence of the polymorphism
reduces affinity for the repressor, with a consequent increase in
transcription [42]. These data indicate that the polymorphism at
this position may influence gene expression and may help explain
the association between the presence of allele TNF-238A and
higher TNF-alpha production observed in this study.
Flow cytometry analysis indicated that CD14
+ and CD8
+ cells
are the major source of TNF-alpha after antigen stimulation. The
number of CD14
+ T lymphocytes expressing TNF-alpha was
significantly higher in cardiac patients, whereas the number of
CD4
+ lymphocytes producing this cytokine was high in patients
with the indeterminate form. The stimulation of CD8
+ T
lymphocytes with exogenous antigens, including T cruzi lysate
antigens, under similar culture conditions has been demonstrated
previously [43,44].
The importance of TNF-alpha as an activator of the
mechanisms involved in parasite elimination [12] and in tissue
injury [10,11] has been clearly demonstrated in experimental
models by biological blockage of the cytokine or in genetically
modified animals. Studies on humans have associated TNF-alpha
with phenomena of tissue injury during the chronic phase of
infection [13]. The present results demonstrate an association
between gene polymorphisms and infection.
In conclusion, the present results suggest that the TNF-238A
allele exerts a significant effect on human susceptibility to
infection. Furthermore, seropositive individuals carrying the
TNF-238A allele produce higher levels of TNF-alpha after antigen
and polyclonal stimulation, suggesting that the presence of the
allele is associated with higher TNF-alphaproductionIn addition to
its trypanocidal activity, TNF-alpha seems to trigger regulatory
networks, such as the induction of IL-10 [34], that permit parasite
escape. The development of clinical forms of Chagas disease may
implicate other genes involved in the delicate balance of immune
response.
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